K. Redlich, S. Hayer, R. Ricci, J. David, M. Tohidast-akrad et al., Osteoclasts are essential for TNF-?????mediated joint destruction, Journal of Clinical Investigation, vol.110, issue.10, pp.1419-1427, 2002.
DOI : 10.1172/JCI0215582

G. Schett, Erosive arthritis, Arthritis Research & Therapy, vol.9, issue.Suppl 1, p.2, 2007.
DOI : 10.1186/ar2166
URL : http://doi.org/10.1186/ar2166

E. Gravallese, Y. Harada, J. Wang, A. Gorn, T. Thornhill et al., Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis, Am J Pathol, vol.152, pp.943-951, 1998.

A. Pettit, H. Ji, V. Stechow, D. Muller, R. Goldring et al., TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis, The American Journal of Pathology, vol.159, issue.5, pp.1689-1699, 2001.
DOI : 10.1016/S0002-9440(10)63016-7

E. Romas, N. Sims, D. Hards, M. Lindsay, J. Quinn et al., Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis, The American Journal of Pathology, vol.161, issue.4, pp.1419-1427, 2002.
DOI : 10.1016/S0002-9440(10)64417-3

A. Pettit, N. Walsh, C. Manning, S. Goldring, and E. Gravallese, RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis, Rheumatology, vol.45, issue.9, pp.1068-1076, 2006.
DOI : 10.1093/rheumatology/kel045

A. Rivollier, M. Mazzorana, J. Tebib, M. Piperno, T. Aitsiselmi et al., Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment, Blood, vol.104, issue.13, pp.4029-4037, 2004.
DOI : 10.1182/blood-2004-01-0041

E. Romas, Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates, Best Practice & Research Clinical Rheumatology, vol.19, issue.6, pp.1065-1079, 2005.
DOI : 10.1016/j.berh.2005.06.008

S. Cohen, R. Dore, N. Lane, P. Ory, C. Peterfy et al., Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis & Rheumatism, vol.27, issue.5, pp.1299-1309, 2008.
DOI : 10.1002/art.23417

D. Heymann, B. Ory, F. Gouin, J. Green, and F. Rédini, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004.
DOI : 10.1016/j.molmed.2004.05.007

D. Reid, J. Devogelaer, K. Saag, C. Roux, C. Lau et al., Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, The Lancet, vol.373, issue.9671, pp.1253-1263, 2009.
DOI : 10.1016/S0140-6736(09)60250-6

P. Herrak, B. Görtz, S. Hayer, K. Redlich, E. Reiter et al., Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis, Arthritis & Rheumatism, vol.44, issue.Suppl 6, pp.2327-2337, 2004.
DOI : 10.1002/art.20384

N. Sims, J. Green, M. Glatt, S. Schlict, T. Martin et al., Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis, Arthritis & Rheumatism, vol.3, issue.7, pp.2338-2346, 2004.
DOI : 10.1002/art.20382

S. Jarrett, P. Conaghan, V. Sloan, P. Papanastasiou, C. Ortmann et al., Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis, Arthritis & Rheumatism, vol.61, issue.5, pp.1410-1414, 2006.
DOI : 10.1002/art.21824

V. Strand, S. Cohen, M. Schiff, A. Weaver, R. Fleischmann et al., Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate, Archives of Internal Medicine, vol.159, issue.21, pp.2542-2550, 1999.
DOI : 10.1001/archinte.159.21.2542

A. Finckh, J. Simard, J. Duryea, M. Liang, J. Huang et al., The effectiveness of anti???tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study, Arthritis & Rheumatism, vol.38, issue.1, pp.54-59, 2006.
DOI : 10.1002/art.21491

J. Bathon, R. Martin, R. Fleischmann, J. Tesser, M. Schiff et al., A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis, New England Journal of Medicine, vol.343, issue.22, pp.1586-1593, 2000.
DOI : 10.1056/NEJM200011303432201

C. Lee, E. Lee, S. Chung, S. Mun, B. Yoo et al., Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor ?B, osteoprotegerin, and receptor activator of nuclear factor ?B ligand, Arthritis & Rheumatism, vol.250, issue.12, pp.3831-3843, 2004.
DOI : 10.1002/art.20637

C. Fan, J. Cool, M. Scherer, B. Foster, T. Shandala et al., Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment, Bone, vol.44, issue.1, pp.61-70, 2009.
DOI : 10.1016/j.bone.2008.09.014

S. Morgan, J. Baggott, W. Bernreuter, R. Gay, R. Arani et al., MTX affects inflammation and tissue destruction differently in the rat AA model, J Rheumatol, vol.28, pp.1476-1481, 2001.

R. Esser, A. Hildebrand, R. Angelo, L. Watts, M. Murphey et al., Measurement of radiographic changes in adjuvant-induced arthritis in rats by quantitative image analysis, Arthritis & Rheumatism, vol.29, issue.1, pp.129-138, 1995.
DOI : 10.1002/art.1780380120

D. Sancho, M. Gómez, F. Viedma, E. Esplugues, M. Gordón-alonso et al., downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis, J Clin Invest, vol.112, pp.69872-882, 2003.

F. Eggelmeijer, S. Papapoulos, H. Van-paassen, B. Dijkmans, R. Valkema et al., Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial, Arthritis & Rheumatism, vol.23, issue.3, pp.396-402, 1996.
DOI : 10.1002/art.1780390307

A. Maccagno, D. Giorgio, E. Roldan, E. Caballero, L. et al., Double Blind Radiological Assessment of Continuous Oral Pamidronic Acid in Patients with Rheumatoid Arthritis, Scandinavian Journal of Rheumatology, vol.17, issue.1, pp.211-214, 1994.
DOI : 10.1016/0140-6736(90)90452-B

H. Valleala, L. Laasonen, M. Koivula, J. Mandelin, C. Friman et al., Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease, J Rheumatol, vol.30, pp.468-473, 2003.

J. Gasser, P. Ingold, A. Venturiere, V. Shen, and J. Green, Long-Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat, Journal of Bone and Mineral Research, vol.21, issue.Suppl, pp.544-551, 2008.
DOI : 10.1359/jbmr.071207

H. Harada, T. Nakayama, T. Nanaka, and T. Katsumata, Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis, Inflammation Research, vol.53, issue.2, pp.45-52, 2004.
DOI : 10.1007/s00011-003-1214-4

M. Yoshida, Y. Kanno, A. Ishisaki, H. Tokuda, K. Hirade et al., Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts, J Rheumatol, vol.32, pp.787-795, 2005.

E. Chan and B. Cronstein, Molecular action of methotrexate in inflammatory diseases, Arthritis Research, vol.4, issue.4, pp.266-273, 2002.
DOI : 10.1186/ar419

B. Cronstein, Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis, Pharmacological Reviews, vol.57, issue.2, pp.163-172, 2005.
DOI : 10.1124/pr.57.2.3

Y. Suzuki, M. Nakagawa, C. Masuda, M. Ide, R. Uehara et al., Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis, J Rheumatol, vol.24, pp.1890-1895, 1997.

A. Ragab, R. Frech, and T. Vietti, Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission, Cancer, vol.72, issue.3, pp.580-585, 1970.
DOI : 10.1002/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M

K. May, S. West, M. Mcdermott, and W. Huffer, The Effect of Low-Dose Methotrexate on Bone Metabolism and Histomorphometry in Rats, Arthritis & Rheumatism, vol.20, issue.2, pp.201-206, 1994.
DOI : 10.1002/art.1780370208

D. Wheeler, R. Griend, . Vander, T. Wronski, G. Miller et al., The short- and long-term effects of methotrexate on the rat skeleton, Bone, vol.16, issue.2, pp.215-221, 1995.
DOI : 10.1016/8756-3282(94)00032-U

A. Schwartz and J. Leonidas, Methotrexate osteopathy, Skeletal Radiology, vol.125, issue.1, pp.13-16, 1984.
DOI : 10.1007/BF00361126

O. Di-munno, M. Mazzantini, L. Sinigaglia, G. Bianchi, G. Minisola et al., Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study, J Rheumatol, vol.31, pp.1305-1309, 2004.

A. Cranney, R. Mckendry, G. Wells, D. Ooi, N. Kanigsberg et al., The effect of low dose methotrexate on bone density, J Rheumatol, vol.28, pp.2395-2399, 2001.

N. Minaur, D. Kounali, S. Vedi, J. Compston, J. Beresford et al., Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density, Rheumatology, vol.41, issue.7, pp.741-749, 2002.
DOI : 10.1093/rheumatology/41.7.741

J. Spadaro, T. Damron, J. Horton, B. Margulies, G. Murray et al., Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge, Journal of Orthopaedic Research, vol.15, issue.5, pp.936-944, 2006.
DOI : 10.1002/jor.20145

L. Yilmaz, K. Ozoran, O. Gündüz, H. Uçan, and M. Yücel, Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids, Rheumatology International, vol.20, issue.2, pp.65-69, 2001.
DOI : 10.1007/s002960000080